Each ml contains: Active substance: Brinzolamide USP 10 mg. Vehicle: Carbomer. Preservative: Purite (Stabilized Oxychloro Complex) 0.05 mg.
Benozol is a sterile ophthalmic suspension containing Brinzolamide for topical administration to the eye. It has a pH of approximately 7.5 and an osmolality of 300 mOsm/kg.
Clinical Pharmacology:
Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbondioxide and the dehydration of carbonic acid. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure (IOP).
Benozol is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Shake well before use.
Insert 1 drop in the affected eye(s) three times daily. It may be used concomitantly with other topical ophthalmic products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.
*Prescription only*
In patients treated with oral carbonic anhydrase inhibitors, rare instances to drug interactions have occurred with high-dose salicylate therapy. Therefore, the potential for such drug interactions should be considered in patients receiving Brinzolamide.
Pregnancy: Pregnancy Category C.
There are no adequate and well-controlled studies in pregnant women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It should be used only if the potential benefit justifies the potential risk to the baby.
One drop in the affected eye(s) 2 times daily in pediatric patient (4 weeks to 5 years age).
No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Although no human data are available, electrolyte imbalance, development of an acidosis state, and possible nervous system effects may occur following oral administration of an overdose. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.
Brinzolamide is a sulfonamide and although administered topically it is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration of Brinzolamide. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Sensitization may occur when a sulfonamide is re-administered irrespective of the route of administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation. Because Brinzolamide and its metabolite are excreted predominantly by the kidney, Brinzolamide is not recommended in renal impairment patients. Brinzolamide- has not been studied in patients with hepatic impairment and should be used with caution in such patients.
Store at below 30°C in a dry place protected from light. Do not touch dropper tip to any surface. It is desirable that the contents should not be used more than one month after first opening of the bottle. Protect from freezing.